Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 1
1951 4
1952 4
1953 4
1954 4
1955 2
1956 3
1957 5
1958 2
1959 2
1960 2
1961 4
1962 2
1963 3
1965 4
1966 1
1967 1
1968 2
1969 3
1970 3
1971 6
1972 5
1973 7
1974 15
1975 16
1976 16
1977 10
1978 13
1979 6
1980 11
1981 10
1982 12
1983 7
1984 14
1985 8
1986 14
1987 8
1988 19
1989 8
1990 14
1991 9
1992 7
1993 4
1994 5
1995 12
1996 11
1997 10
1998 8
1999 9
2000 6
2001 7
2002 7
2003 8
2004 9
2005 13
2006 22
2007 21
2008 29
2009 28
2010 25
2011 39
2012 35
2013 37
2014 59
2015 48
2016 56
2017 70
2018 52
2019 66
2020 101
2021 123
2022 118
2023 114
2024 92
2025 46

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,409 results

Results by year

Filters applied: . Clear all
Page 1
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Sartor O, et al. Among authors: herrmann k. N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. N Engl J Med. 2021. PMID: 34161051 Free PMC article. Clinical Trial.
Radiotheranostics: a roadmap for future development.
Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, Gambhir SS, Hricak H, Weissleder R. Herrmann K, et al. Lancet Oncol. 2020 Mar;21(3):e146-e156. doi: 10.1016/S1470-2045(19)30821-6. Lancet Oncol. 2020. PMID: 32135118 Free PMC article. Review.
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H,… See abstract for full author list ➔ Gillessen S, et al. Among authors: herrmann k. Eur Urol. 2023 Mar;83(3):267-293. doi: 10.1016/j.eururo.2022.11.002. Epub 2022 Dec 6. Eur Urol. 2023. PMID: 36494221 Free PMC article.
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K; PSMAfore Investigators. Morris MJ, et al. Among authors: herrmann k. Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15. Lancet. 2024. PMID: 39293462 Clinical Trial.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, Sandhu S, Kratochwil C, Esfandiari R, Tauber R, Zeldin A, Rathke H, Armstrong WR, Robertson A, Thin P, D'Alessandria C, Rettig MB, Delpassand ES, Haberkorn U, Elashoff D, Herrmann K, Czernin J, Hofman MS, Fendler WP, Eiber M. Gafita A, et al. Among authors: herrmann k. Lancet Oncol. 2021 Aug;22(8):1115-1125. doi: 10.1016/S1470-2045(21)00274-6. Epub 2021 Jul 8. Lancet Oncol. 2021. PMID: 34246328 Free article.
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).
Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. Kratochwil C, et al. Among authors: herrmann k. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22. Eur J Nucl Med Mol Imaging. 2019. PMID: 31440799
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer.
Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, Oprea-Lager DE, Oyen WJ, Rouvière O, Mottet N, Bjartell A. Fanti S, et al. Among authors: herrmann k. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):469-476. doi: 10.1007/s00259-020-04934-4. Epub 2020 Jul 2. Eur J Nucl Med Mol Imaging. 2021. PMID: 32617640 Free PMC article.
Coronavirus SARS-CoV-2: Empfehlungen für die nuklearmedizinische Versorgung in nuklearmedizinischen Kliniken/Abteilungen mit Therapiestation und Praxen, Instituten sowie Ordinationen.
Krause BJ, Bartenstein P, Freudenberg LS, Herrmann K, Jonas G, Luster M, Moka D, Schäfer W, Schwarzenböck SM, Meyer PT. Krause BJ, et al. Among authors: herrmann k. Nuklearmedizin. 2020 Apr;59(2):e1-e4. doi: 10.1055/a-1147-6722. Epub 2020 Apr 2. Nuklearmedizin. 2020. PMID: 32241030 German. No abstract available.
[Hybrid imaging].
Umutlu L, Herrmann K, Herold C. Umutlu L, et al. Among authors: herrmann k. Radiologe. 2020 May;60(5):375. doi: 10.1007/s00117-020-00677-3. Radiologe. 2020. PMID: 32342152 German. No abstract available.
SPECT/CT.
Buck AK, Nekolla S, Ziegler S, Beer A, Krause BJ, Herrmann K, Scheidhauer K, Wester HJ, Rummeny EJ, Schwaiger M, Drzezga A. Buck AK, et al. Among authors: herrmann k. J Nucl Med. 2008 Aug;49(8):1305-19. doi: 10.2967/jnumed.107.050195. Epub 2008 Jul 16. J Nucl Med. 2008. PMID: 18632825 Free article.
1,409 results